PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple myeloma |
| Symptom | C0040038|thromboembolism |
| Sentences | 13 |
| PubMedID- 23903204 | Melisse, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. |
| PubMedID- 22511493 | We found multiple myeloma patients with venous thromboembolism to have a higher mortality at 1-, 5-, and 10-years of follow up compared with those without, with hazard ratios of 2.9 (95% confidence interval (ci) 2.4-3.5), 1.6 (95% ci: 1.5-1.8), and 1.6 (95% ci: 1.4-1.7), respectively. |
| PubMedID- 19901114 | Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. |
| PubMedID- 21859556 | Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. |
| PubMedID- 21255254 | Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. |
| PubMedID- 20874693 | The background rate of thromboembolism is 4-11% in patients with multiple myeloma, which increases to 15-20% in patients who received intensive treatment with thalidomide. |
| PubMedID- 21720994 | Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. |
| PubMedID- 20385482 | Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. |
| PubMedID- 26432650 | This study focused on the clinical outcomes in multiple myeloma (mm) patients with venous thromboembolism (vte) who received low-molecular-weight heparin (dalteparin) therapy. |
| PubMedID- 23014188 | Purpose of review: this review summarizes the current knowledge of the epidemiology, prophylaxis, and treatment of venous thromboembolism (vte) in patients with lymphoma, multiple myeloma or acute leukemia. |
| PubMedID- 25632017 | This study aims to determine the incidence of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory drug therapy in the ambulatory setting at uc health and to investigate adherence with guidelines developed by the national comprehensive cancer network for venous thromboembolism prevention in this patient population. |
| PubMedID- 26177588 | Lenalidomide treatment in combination with dexamethasone and/or chemotherapy is associated with a significant risk of venous thromboembolism (vte) in patients with multiple myeloma (mm). |
| PubMedID- 24599441 | Venous thromboembolism in multiple myeloma. |
Page: 1